Antares Pharma Appoints Joseph Renda as Senior Vice : compar

Antares Pharma Appoints Joseph Renda as Senior Vice


Antares Pharma Appoints Joseph Renda as Senior Vice President of Commercial
May 06, 2021 07:15 ET
| Source:
Antares Pharma, Inc.
Antares Pharma, Inc.
Ewing, New Jersey, UNITED STATES
EWING, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a specialty pharmaceutical company, today announced the appointment of Joseph V. Renda as Senior Vice President of Commercial. Mr. Renda succeeds Patrick Shea who resigned to pursue other interests.
Mr. Renda has had a successful career in leading commercial sales, marketing, and operations at large and mid-sized pharmaceutical companies. Prior to joining Antares, Mr. Renda was Vice President, U.S. Sales Autoimmune and Rare Disease at Mallinckrodt Pharmaceuticals where he led a 200-person organization responsible for over $1B in annual sales and managed 5 unique therapeutic areas and institutional account teams. From 2012 to 2018, he held various positions of increasing responsibility at Novo Nordisk including Marketing Brand Director, Women’s Health Care and leading the commercial operations and effectiveness function responsible for a 150-person sales force. He was ultimately promoted to Vice President, U.S. Sales Biopharmaceutical Division leading a national sales team with over $600M in annual sales. Prior to that, he was Regional Business Director at Pfizer managing one of the largest U.S. sales regions with 175 sales and account representatives after serving in varying director and operational roles. He also previously served as Manager, U.S. Urology Marketing and Alliances at the Pharmacia Corporation and began his career in sales at The Upjohn Company. Mr. Renda earned his Bachelor of Science degree from Pennsylvania State University.

Related Keywords

Canada , Israel , Josephv Renda , Patrick Shea , Women Health Care , Nasdaq , Teva Pharmaceutical Industries Ltd , Company Annual Report On Form , Pfizer , Pfizer Inc , Idorsia Pharmaceuticals , Upjohn Company , Rare Disease At Mallinckrodt Pharmaceuticals , Us Sales Biopharmaceutical Division , Ferring Pharmaceuticals , Pennsylvania State University , Pharmacia Corporation , Exchange Commission , Corporate Communications , Antares Pharma , Idorsia Pharmaceuticals Ltd , Antares Pharma Inc , Novo Nordisk , Senior Vice President , Vice President , Rare Disease , Mallinckrodt Pharmaceuticals , Marketing Brand Director , Health Care , Biopharmaceutical Division , Regional Business Director , Pennsylvania State , Chief Executive Officer , Teva Pharmaceutical Industries , Sumatriptan Injection , Private Securities Litigation Reform Act , Hercules Capital , Annual Report , கனடா , இஸ்ரேல் , பேட்ரிக் ஷியா , பெண்கள் ஆரோக்கியம் பராமரிப்பு , நாஸ்டாக் , தேவா மருந்து தொழில்கள் லிமிடெட் , நிறுவனம் ஆண்டு அறிக்கை ஆன் வடிவம் , ஃபைசர் , ஃபைசர் இன்க் , அப்‌ஜாந் நிறுவனம் , ஃபெர்ரிங் மருந்துகள் , பென்சில்வேனியா நிலை பல்கலைக்கழகம் , பரிமாற்றம் தரகு , பெருநிறுவன தகவல்தொடர்புகள் , அண்டர்ஸ் பார்மா , அண்டர்ஸ் பார்மா இன்க் , மூத்தவர் துணை ப்ரெஸிடெஂட் , துணை ப்ரெஸிடெஂட் , ரேர் நோய் , ஆரோக்கியம் பராமரிப்பு , பிராந்திய வணிக இயக்குனர் , பென்சில்வேனியா நிலை , தலைமை நிர்வாகி அதிகாரி , தேவா மருந்து தொழில்கள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஹெர்குலஸ் மூலதனம் , ஆண்டு அறிக்கை ,

© 2025 Vimarsana